
[IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1
In previously untreated adults with HIV-1, initiating therapy with either DOR/ISL or BIC/FTC/TAF results in comparable enhancements in overall health status.
















